Compare TRDA & NCMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | NCMI |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.5M | 306.0M |
| IPO Year | 2021 | 2006 |
| Metric | TRDA | NCMI |
|---|---|---|
| Price | $7.37 | $3.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $21.00 | $5.63 |
| AVG Volume (30 Days) | 279.1K | ★ 489.0K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 3.36% |
| EPS Growth | N/A | ★ 52.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,421,000.00 | N/A |
| Revenue This Year | $39.97 | $11.20 |
| Revenue Next Year | $50.80 | $6.22 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $2.80 |
| 52 Week High | $16.45 | $5.14 |
| Indicator | TRDA | NCMI |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 64.71 |
| Support Level | $5.75 | $3.77 |
| Resistance Level | $10.82 | $4.02 |
| Average True Range (ATR) | 0.52 | 0.14 |
| MACD | 0.26 | 0.02 |
| Stochastic Oscillator | 77.36 | 81.65 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.